DGXQuest Diagnostics
The financials
Quest Diagnostics by the numbers
Quest Diagnostics (DGX) reported revenue of $3.10B in Q3 2026 (quarter ended Sep 30, 2026), up 10.0% from the same quarter a year earlier. That came with a gross margin of 34% and net income of $312M (10% of revenue). For the full year FY2025, revenue was $11.0B (+12% year on year) and net income $992M. Its largest segment in Q2 2026 (quarter ended Jun 30, 2026) was Diagnostic Information Services Business at $2.98B, 98% of the disclosed total, well ahead of All Other at 2.1%. The next results filing is expected around Jan 11, 2027, the same week as a year ago.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $3.10B | $2.82B | +10.0% |
| Gross profit | $1.04B | $949M | +9.8% |
| Operating income | $479M | $386M | +24% |
| Net income | $312M | $245M | +27% |
| Diluted EPS | $2.78 | $2.16 | +29% |
| Operating | Revenue | Share |
|---|---|---|
| Diagnostic Information Services Business | $2.98B | 98% |
| All Other | $65M | 2.1% |
Over its last three fiscal years Quest Diagnostics booked income tax of 23.0% of its pretax profit, close to the 21.3% median for US companies in our tax study.
Business segments
Revenue split by operating segment, from SEC XBRL filings.
- Diagnostic Information Services Business$2.98B$2.98Bvs last quarter +5.2%vs a year ago +10%+5.2%+10%
- All Other$65.0M$65.0Mvs last quarter +3.2%vs a year ago +4.8%+3.2%+4.8%
Diagnostics & Research
The closest names by size in the same industry